Firmonertinib

DRUG6 trials

Conditions

Adjuvant TreatmentAdvanced Non-Small-Cell Lung CancerCentral Nervous System MetastasisEGFR P-Loop and Alpha C-Helix CompressingEGFR PACCEGFR Positive Non-small Cell Lung CancerEGFR Uncommon MutationsIntrathecal Chemotherapy

Phase 2

Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma

RecruitingNCT07314216

Hunan Cancer HospitalEGFR Uncommon Mutations, NSCLC (Non-small Cell Lung Carcinoma), Stage III

Start: 2026-06-22End: 2030-12-31Target: 15Updated: 2026-07-08

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

Not yet recruitingNCT07661173

Anhui Provincial Cancer HospitalNon Small Cell Lung Cancer

Start: 2026-06-06End: 2031-05-06Target: 154Updated: 2026-06-22

Phase 3

A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

RecruitingNCT07010419

Allist Pharmaceuticals, Inc.Adjuvant Treatment, NSCLC

Start: 2025-05-28End: 2032-04-30Target: 338Updated: 2026-08-13

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

RecruitingNCT07185997

ArriVent BioPharma, Inc.Advanced Non-Small-Cell Lung Cancer, EGFR PACC, EGFR P-Loop and Alpha C-Helix Compressing +3

Start: 2025-12-17End: 2030-12-01Target: 480Updated: 2026-09-01

Phase 4

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

RecruitingNCT07092202

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyIntrathecal Chemotherapy, Leptomeningeal Metastasis, NSCLC +1

Start: 2025-04-15End: 2027-11-01Target: 40Updated: 2025-07-29

Unknown Phase

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

CompletedNCT07239102

Beijing Tiantan HospitalCentral Nervous System Metastasis, EGFR Positive Non-small Cell Lung Cancer, Leptomeningeal Metastasis

Start: 2020-01-01End: 2025-10-01Updated: 2025-11-20

Related Papers

ALPACCA: Phase 3 trial of firmonertinib vs investigator’s choice of EGFR inhibitor as first-line treatment for locally advanced or metastatic NSCLC with EGFR P-loop and alpha c-helix compressing (PACC) uncommon mutations (FURMO-006).

Journal of Clinical Oncology2026-05-28